Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.
Revach OY, Cicerchia AM, Shorer O, Palin CA, Petrova B, Anderson S, Liu B, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Brook JR, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW.
Revach OY, et al. Among authors: fang j.
Cell Rep Med. 2025 Jun 19:102210. doi: 10.1016/j.xcrm.2025.102210. Online ahead of print.
Cell Rep Med. 2025.
PMID: 40578364
Free article.